Mira Pharmaceuticals Announces Selection Of Neuropathic Pain As Indication For Ketamir-2 And Submits Pre-IND Meeting Request To FDA
Mira Pharmaceuticals Announces Selection Of Neuropathic Pain As Indication For Ketamir-2 And Submits Pre-IND Meeting Request To FDA
米拉制藥宣佈神經病性疼痛被選爲Ketamir-2的適應症，並向FDA提交了預IND會議請求。
Mira Pharmaceuticals, Inc. (NASDAQ:MIRA) today announced that it has selected neuropathic pain as the primary indication for its novel oral ketamine analog, Ketamir-2. The Company has submitted a pre-Investigational New Drug (pre-IND) meeting request to the U.S. Food and Drug Administration (FDA) and anticipates the meeting to occur in October 2024. This selection marks a significant milestone as Mira Pharmaceuticals advances toward its IND submission, with plans to begin human trials in the first quarter of 2025.
米拉制藥公司（納斯達克股票代碼：MIRA）今天宣佈，它已選擇神經性疼痛作爲其新型口服氯胺酮類似物Ketamir-2的主要適應症。該公司已向美國食品藥品監督管理局（FDA）提交了研究前新藥（Pre-IND）會議請求，預計會議將於2024年10月舉行。這一選擇標誌着Mira Pharmaceuticals在提交IND方面取得進展的一個重要里程碑，並計劃於2025年第一季度開始人體試驗。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間